Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 23;20:426. doi: 10.1186/s12967-022-03633-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 3 — MiR-136-5p promotes EMT and fibrosis in LUAD. A GEO database analysis-miR-136-5p expression differences in LUAD and normal lung tissues. B Analysis of miR-136-5p expression in relation to survival of LUAD using GEO database. C RT-qPCR detection of miR-136-5p expression differences in BEAS-2B and A549. D MiR-136-5p inhibitor treatment A549 after RT-qPCR to detect the mRNA expression of miR-136-5p. E Stable knockdown of miR-136-5p and RT-qPCR to detect the knockdown efficiency of miR-136-5p. F MiR-136-5p inhibitor treatment of A549 after RT-qPCR to detect the expression of EMT and fibrosis markers. G, H MiR-136- 5p inhibitor treatment of A549, WB to detect the protein expression of TGF-β1, E-Cadherin, Vimentin, ACTA2 and COL1A1. Statistical quantification by ImageJ software. I Stable knockdown of miR-136-5p followed by RT-qPCR to detect the expression of EMT and fibrosis markers. J, K After stably knocking out miR-136-5p, the expression of related proteins was detected by WB and statistically quantified by ImageJ software. L, M Wound scratch assay was performed to monitor cell migration after MiR-136-5p inhibitor treatment of A549 cells, Statistical data are shown. N, O Invasion assay was performed to determine cell invasion after miR-136-5p inhibition treatment of A549 cells. P, Q MiR-136-5p inhibitor A549 was followed by an Immunofluorescence assay performed to detect the expression of the fibrosis-associated protein. Statistical data are shown. R Subcutaneous tumorigenic demonstration in nude mice. S Tumor weights were represented as the means of tumor weights ± SD. T RT-qPCR to confirm the effect of miR-136-5p knockdown in tumor tissues. U, V WB to detect the expression of miR-136-5p stable knockdown of TGF-β1, E-Cadherin, Vimentin, ACTA2 and COL1A1 in tumor tissues. Statistical data are shown. W The tumor sections underwent IHC staining and H&E staining